Your browser doesn't support javascript.
loading
Eficácia e tolerabilidade da associação captopril + hidroclorotiazida no tratamento da hipertensão arterial leve a moderada. Estudo multicêntrico / Efficacy and tolerability of the association of efficacy and tolerability of the association of captopril + hydrochlorothiazide in the treatment of mild-to-moderate hypertension. A multicenter trial hypertension. A multicenter trial
Velasco-Cornejo, Ivan Francisco; Martin, Luis Cuadrado; Franco, Roberto Jorge da Silva.
  • Velasco-Cornejo, Ivan Francisco; Universidade Estadual Paulista (UNESP). Faculdade de Medicina. Botucatu. BR
  • Martin, Luis Cuadrado; Universidade Estadual Paulista (UNESP). Faculdade de Medicina. Botucatu. BR
  • Franco, Roberto Jorge da Silva; Universidade Estadual Paulista (UNESP). Faculdade de Medicina. Botucatu. BR
Arq. bras. cardiol ; 64(6): 571-575, Jun. 1995.
Artigo em Português | LILACS | ID: lil-319353
ABSTRACT
PURPOSE--To evaluate the antihypertensive efficacy and tolerability of captopril 50 mg + hydrochlorothiazide 25 mg daily in mild to moderate primary hypertension. METHODS--Out-patients (n = 471) with mild to moderate hypertension, diastolic blood pressure (DBP) 95-115 mmHg, with 15 days of washout, were included to the treatment initially with half tablet of the association of captopril 50 mg + hydrochlorothiazide 25 mg once daily, for 30 days. After this period, patients with DBP > 90 mmHg had the dosage duplicated, while the others had the same dosage for 60 days more. Evaluation was performed 15 days before and then every month during active drug. RESULTS--Twenty six patients were withdrawn, 13 (2.7) by adverse effects and 13 by protocol violation. At the end of the wash-out period, the blood pressure (BP), 162 +/- 16/103 +/- 6 mmHg decreased significantly at the 30th day to 146 +/- 14/92 +/- 8 mmHg (p < 0.001 vs 0th day); 139 +/- 12/86 +/- 7 mmHg at the 60th day, (p < 0.001 vs 30th day), and further to 136 +/- 11/84 +/- 5 mmHg, (p < 0.001 vs day 0) till the end of the 90th day. Antihypertensive efficacy (DBP < or = 90 mmHg and decreased of the DBP > or = 10 mmHg) was obtained in 82 of the patients. There was no difference in BP control considering race, hypertension level, previous antihypertensive treatment and obesity. Cough (4) was the main adverse event. CONCLUSION--Captopril + hydrochlorothiazide was effective and safe in the treatment of mild to moderate hypertension. The favorable response was observed in 82 of the patients independently of race, hypertensive level, previous antihypertensive treatment and obesity. Low incidence of side effects was reported, with no difference from others reported in the literature.
Assuntos

Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Captopril / Hidroclorotiazida / Hipertensão / Anti-Hipertensivos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica Limite: Adolescente / Adulto / Aged80 / Feminino / Humanos / Masculino Idioma: Português Revista: Arq. bras. cardiol Assunto da revista: Cardiologia Ano de publicação: 1995 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Universidade Estadual Paulista (UNESP)/BR

Similares

MEDLINE

...
LILACS

LIS

Texto completo: DisponíveL Índice: LILACS (Américas) Assunto principal: Captopril / Hidroclorotiazida / Hipertensão / Anti-Hipertensivos Tipo de estudo: Ensaio Clínico Controlado / Guia de Prática Clínica Limite: Adolescente / Adulto / Aged80 / Feminino / Humanos / Masculino Idioma: Português Revista: Arq. bras. cardiol Assunto da revista: Cardiologia Ano de publicação: 1995 Tipo de documento: Artigo País de afiliação: Brasil Instituição/País de afiliação: Universidade Estadual Paulista (UNESP)/BR